PCSK9-Targeting Therapies and Mortality: A Systematic Review and Meta-Analysis of Randomized Trials.
PCSK9-targeting therapies were associated with lower all-cause mortality and fewer ischemic events across trial populations, and the predominant contribution of large cardiovascular outcome trials enrolling populations with known atherosclerosis and using PCSK9 antibodies limits the ability to infer a survival benefit.